If a PET Scan Is Negative, Does That Mean No Cancer?

A negative PET scan is reassuring, but it does not guarantee the absence of cancer. PET scans are powerful tools that detect areas of unusually high metabolic activity in the body, and most cancers light up brightly on these images. However, several well-documented factors can cause a real cancer to go undetected, producing what doctors call a false-negative result. The reasons range from the tumor being too small to the cancer type being metabolically quiet, and understanding these blind spots matters for anyone trying to make sense of their scan results.

How a PET Scan Finds Cancer

The standard PET scan used in cancer imaging relies on a radioactive sugar molecule called FDG (fluorodeoxyglucose). Cancer cells tend to burn through glucose at a much higher rate than normal cells because they have rewired their metabolism to fuel rapid, unchecked growth. When FDG is injected into your bloodstream, cancer cells gobble it up just like regular glucose, but the radioactive tag allows the scanner to see where the sugar is concentrating. A cluster of cells consuming far more sugar than their neighbors shows up as a bright spot on the image.¹

This approach works well for many cancers, but it has an inherent assumption baked into it: the cancer must be metabolically greedy enough to stand out from the background noise of normal tissue. When that assumption holds, PET scans are excellent at spotting disease. When it doesn’t, cancers can hide in plain sight.

The Size Threshold Problem

Every imaging technology has a resolution floor, and PET scanners are no exception. Modern clinical PET scanners have a spatial resolution limit of roughly 4 millimeters, which translates to reliably detecting tumors with a volume of about 0.2 milliliters, or around 7 millimeters in diameter, assuming the tumor-to-background contrast is favorable.² In practice, tumors need to be somewhat larger than this theoretical minimum for consistent detection. A study of melanoma patients found that FDG-PET reliably identified lymph node metastases only when tumor deposits were larger than about 80 cubic millimeters, with sensitivity dropping off quickly below that size.³

What this means in real terms is that a very early-stage cancer, or a tiny cluster of cancer cells in a lymph node, can easily fall below the scanner’s detection threshold. A tumor the size of a small pea might register clearly, while one the size of a grain of rice might not. This is one of the most straightforward reasons a PET scan can come back clean even when cancer is present: the disease exists, but it is simply too small to see.

Cancers That Don’t Light Up

Not all cancers are equally hungry for glucose. Some tumor types have inherently low metabolic activity, which means they absorb less FDG and produce a weaker signal on the scan. Certain thoracic tumors illustrate this well: bronchioloalveolar carcinomas (a subtype of lung cancer), carcinoid tumors, and low-grade lymphomas have all been documented to produce false-negative PET results because of their relatively slow metabolic rates.⁴ These cancers are still growing and still dangerous, but they aren’t burning through glucose fast enough to stand out on the scan.

Breast cancer offers another clear example. Invasive lobular carcinoma, the second most common type of breast cancer, tends to produce lower FDG uptake values than the more common invasive ductal carcinoma. One study comparing the two found that PET/CT detected about 75% of lobular tumors compared to roughly 84% of ductal tumors.⁵ That one-in-four miss rate for lobular cancers is a meaningful gap, and it highlights that the specific histological type of cancer you have can influence whether PET catches it.

Prostate cancer is perhaps the most well-known blind spot for standard FDG-PET. Many prostate tumors simply don’t take up enough FDG to be visible, which is why prostate cancer staging has historically relied on other imaging methods and why specialized tracers have been developed for it.⁶

When Your Blood Chemistry Gets in the Way

Your body’s metabolic state at the time of the scan can directly affect whether a cancer shows up. The most important factor here is blood sugar. FDG is chemically similar to glucose, so the two compete for the same uptake pathways in cells. When blood glucose levels are high, the tumor’s cells absorb more of the real glucose circulating in the bloodstream and less of the FDG tracer. The result is a weaker signal from the tumor, potentially weak enough to be missed entirely.⁷ This is why you are told to fast before a PET scan and why technologists check your blood sugar beforehand. If you have poorly controlled diabetes, the risk of a false-negative result goes up.

Certain medications can create problems too. Metformin, one of the most commonly prescribed diabetes drugs, causes intense, widespread FDG uptake throughout the colon and, to a lesser degree, the small intestine. This flood of background activity in the gut can mask gastrointestinal cancers that would otherwise be visible.⁸ If you take metformin, your doctor may ask you to stop it temporarily before a PET scan, though the specific protocol varies by institution. The broader point is that the scan is not just reading the tumor; it’s reading your whole metabolic environment, and anything that shifts that environment can affect the results.

The Breathing Problem

A PET scan takes several minutes to acquire images, and during that time, you are breathing. This seemingly trivial fact creates a real technical challenge, especially for tumors in the chest and upper abdomen. A tumor that moves with every breath gets smeared across the image, much like a person moving during a long-exposure photograph. The blurring reduces the apparent brightness of the lesion and makes it look larger but dimmer than it actually is.⁹

The numbers here are striking. For lesions about 1 centimeter across subjected to typical breathing motion, respiratory movement can cause the peak signal intensity to be underestimated by an average of 28%, while the apparent tumor volume gets overestimated by an average of 130%.¹⁰ Smaller lesions are more sensitive to this effect than larger ones. A borderline-detectable small tumor near the base of a lung, where breathing motion is greatest, could have its signal diluted enough to fall below the detection threshold. Current response criteria used to evaluate PET scans don’t formally account for respiratory motion, which is a recognized gap in the field.⁹

Location Matters

Certain parts of your body naturally absorb a lot of FDG regardless of whether cancer is present. Your brain, heart, kidneys, bladder, and liver all have high baseline metabolic activity, which means tumors in or near these organs can be harder to distinguish from the normal background signal. When a cancer is adjacent to one of these metabolically active structures, the tumor’s signal can blend into the surrounding “noise.” For diseases located near these physiologic uptake sites, PET scans generally need to be complemented with other imaging methods to minimize false-negative findings.⁴

Brain tumors are a classic example. The brain consumes roughly 20% of the body’s glucose at rest, so the entire organ glows brightly on a standard FDG-PET scan. A brain tumor has to be dramatically more metabolically active than already-hungry brain tissue to stand out. This is why brain tumor imaging often relies heavily on MRI rather than PET, or uses specialized tracers that don’t have the same high-background problem.

Newer Tracers That See What FDG Misses

The limitations of FDG have driven development of alternative PET tracers designed to image specific cancer types more precisely. One of the most promising is fluoroestradiol (FES), a tracer that targets estrogen receptors rather than glucose metabolism. For estrogen-receptor-positive breast cancer, FES-PET has shown higher detection sensitivity than standard FDG-PET for metastases in lymph nodes, bone, lung, and soft tissue.¹¹ FES-PET is also particularly useful for detecting orbital and intracranial metastases, where the brain’s high FDG background would normally obscure the signal, because FES doesn’t accumulate in normal brain tissue the way FDG does.¹²

For prostate cancer, PSMA-targeted tracers have transformed the diagnostic landscape over the past several years. These tracers bind to prostate-specific membrane antigen, a protein found on prostate cancer cells, rather than relying on glucose metabolism. The result is dramatically better sensitivity for prostate cancer compared to FDG. Other specialized tracers exist for neuroendocrine tumors, certain brain tumors, and other cancers that FDG struggles with.⁶ The takeaway is that “PET scan” is not a single test with a single set of capabilities. The tracer used changes what the scan can and cannot see, and if your cancer type is known to be FDG-quiet, asking your oncologist about alternative tracers is a reasonable conversation to have.

When Imaging Reaches Its Limits

There are situations where no imaging test, PET or otherwise, can detect residual cancer. After surgery or chemotherapy, microscopic clusters of cancer cells may persist in the body at volumes far below anything a scanner can resolve. This is called minimal residual disease, and it represents cancer at a scale where individual cells or tiny cell clusters are scattered through tissue, invisible to every conventional imaging modality.

Liquid biopsy is an emerging approach to this problem. Rather than trying to see the cancer, liquid biopsies look for molecular traces it sheds into the bloodstream, particularly circulating tumor DNA. These tumor-specific genetic fragments can indirectly reveal the presence of residual disease that standard imaging and clinical evaluation cannot identify.¹³ Liquid biopsies are not yet standard practice for most cancers, but they are increasingly used in clinical trials and certain treatment-monitoring scenarios. For someone with a negative PET scan who remains at high risk of recurrence, liquid biopsy may eventually become an important complementary tool.

Making Sense of a Negative Result

If your PET scan comes back negative, the practical question is how much weight to put on that result given your specific situation. A few factors make the scan more trustworthy: if the cancer type you’re being evaluated for is known to be highly FDG-avid, if your blood sugar was well controlled before the scan, and if the area of concern is in a body region without heavy background uptake, then a negative result carries substantial reassurance. The scan did what it’s designed to do under favorable conditions.

Conversely, factors that warrant more caution include having a cancer type known to be metabolically quiet (lobular breast cancer, low-grade lymphoma, certain lung subtypes, prostate cancer), having had uncontrolled blood glucose at the time of the scan, or being evaluated for very small or early-stage disease. In these situations, your oncologist may recommend additional imaging, biopsy, or closer surveillance rather than accepting the PET result at face value.

PET scans also play a major role in assessing how well treatment is working. Criteria called PERCIST have been developed specifically for evaluating treatment response on PET, and research suggests that PET-based response criteria are more sensitive at detecting both complete remission and disease progression compared to criteria based on tumor size alone.¹⁴ A negative PET after chemotherapy, for instance, is generally a strong positive sign for FDG-avid cancers, but the same caveats about tumor type and size still apply.

Why Your Doctor Doesn’t Rely on One Test Alone

Oncologists rarely make major decisions based on a single scan in isolation. Cancer diagnosis and monitoring typically involve layering multiple types of evidence: imaging studies (PET, CT, MRI, ultrasound), blood markers, pathology from biopsies, genetic testing, and clinical examination. Each of these tools has its own strengths and blind spots. PET excels at surveying the whole body for metabolically active disease in a single session, but MRI provides better soft-tissue detail, CT offers better anatomical resolution, and biopsy gives a definitive tissue-level answer.

The false-negative rate of any single test is precisely why this layered approach exists. A PET scan that misses a small lobular breast cancer metastasis in the liver might be caught by a contrast-enhanced MRI. A lung nodule blurred by respiratory motion on PET might be clearly resolved on a dedicated chest CT. The most dangerous misunderstanding a patient can have is treating any single negative result as absolute proof of absence. A negative PET scan shifts the probability that cancer is present, sometimes dramatically, but it doesn’t eliminate it. How far it shifts that probability depends on all the factors covered here: tumor biology, size, location, your metabolic state, and which tracer was used. Your oncologist weighs all of those variables when interpreting the result and deciding what comes next.

1
AJR Am J Roentgenol. Metabolic PET Imaging in Oncology
2
PubMed Central. Limits of Tumor Detectability in Nuclear Medicine and PET
3
PubMed. FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volume
4
PubMed Central. False positive and false negative FDG-PET scans in various thoracic diseases
5
PubMed Central. Effectiveness of Breast MRI and (18)F-FDG PET/CT for the Preoperative Staging of Invasive Lobular Carcinoma versus Ductal Carcinoma
6
European Journal of Hybrid Imaging. Non-FDG PET/CT in Diagnostic Oncology: a pictorial review
7
Korean Journal of Radiology. False Positive and False Negative FDG-PET Scans in Various Thoracic Diseases
8
PubMed. Metformin may be associated with false-negative cancer detection in the gastrointestinal tract on PET/CT
9
PubMed Central. The clinical significance and management of lesion motion due to respiration during PET/CT scanning
10
Physics in Medicine & Biology. The impact of respiratory motion on tumor quantification and delineation in static PET/CT imaging
11
PubMed. Diagnostic effectiveness of [(18)F]Fluoroestradiol PET/CT in oestrogen receptor-positive breast cancer: the key role of histopathology
12
PubMed Central. 18F-FES PET/CT Improves the Detection of Intraorbital Metastases in Estrogen-Receptor-Positive Breast Cancer
13
PubMed Central. Liquid Biopsy to Detect Minimal Residual Disease: Methodology and Impact
14
PubMed Central. PET/CT evaluation of response to chemotherapy in non-small cell lung cancer: PET response criteria in solid tumors (PERCIST) versus response evaluation criteria in solid tumors (RECIST)